Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Sehgal, S. Dhooria, Hansraj Choudhary, A. Aggarwal, M. Garg, A. Chakrabarti, R. Agarwal (2019)
Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
N. Tochigi, T. Ishiwatari, Y. Okubo, T. Ando, Minoru Shinozaki, Kyoko Aki, Kyoko Gocho, Y. Hata, S. Murayama, M. Wakayama, T. Nemoto, Y. Hori, K. Shibuya (2015)
Histological study of chronic pulmonary aspergillosisDiagnostic Pathology, 10
( KosmidisC DenningDW . The clinical spectrum of pulmonary aspergillosis. Postgr Med J 2015; 91: 270–277.)
KosmidisC DenningDW . The clinical spectrum of pulmonary aspergillosis. Postgr Med J 2015; 91: 270–277.KosmidisC DenningDW . The clinical spectrum of pulmonary aspergillosis. Postgr Med J 2015; 91: 270–277., KosmidisC DenningDW . The clinical spectrum of pulmonary aspergillosis. Postgr Med J 2015; 91: 270–277.
( BongominF HarrisC HayesG , et al. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One 2018; 13: e0193732.29634721)
BongominF HarrisC HayesG , et al. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One 2018; 13: e0193732.29634721BongominF HarrisC HayesG , et al. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One 2018; 13: e0193732.29634721, BongominF HarrisC HayesG , et al. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One 2018; 13: e0193732.29634721
K. Koyama, Nobuharu Ohshima, J. Suzuki, M. Kawashima, K. Takeda, T. Ando, R. Sato, H. Nagai, H. Matsui, K. Ohta (2014)
Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 20 6
Khaled Al-shair, Graham Atherton, D. Kennedy, G. Powell, D. Denning, A. Caress (2013)
Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis.Chest, 144 2
L. Jain, D. Denning (2006)
The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.The Journal of infection, 52 5
( JonesPW . Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J 1994; 7: 55–62.8143833)
JonesPW . Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J 1994; 7: 55–62.8143833JonesPW . Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J 1994; 7: 55–62.8143833, JonesPW . Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J 1994; 7: 55–62.8143833
C. Kosmidis, E. Muldoon (2017)
Challenges in the management of chronic pulmonary aspergillosis.Medical mycology, 55 1
P. Rohatgi, N. Rohatgi (1984)
Clinical Spectrum of Pulmonary AspergillosisSouthern Medical Journal, 77
D. Denning, Kostantinos Riniotis, R. Dobrashian, H. Sambatakou (2003)
Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37 Suppl 3
( AgarwalR VishwanathG AggarwalAN , et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56: 559–570.23496375)
AgarwalR VishwanathG AggarwalAN , et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56: 559–570.23496375AgarwalR VishwanathG AggarwalAN , et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56: 559–570.23496375, AgarwalR VishwanathG AggarwalAN , et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56: 559–570.23496375
( TochigiN IshiwatariT OkuboY , et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol 2015; 10: 153.26334307)
TochigiN IshiwatariT OkuboY , et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol 2015; 10: 153.26334307TochigiN IshiwatariT OkuboY , et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol 2015; 10: 153.26334307, TochigiN IshiwatariT OkuboY , et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol 2015; 10: 153.26334307
P. Jones (1994)
Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group.The European respiratory journal, 7 1
( Al-ShairK AthertonGTW KennedyD , et al. Validity and reliability of the St. George’s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2013; 144: 623–631.23188518)
Al-ShairK AthertonGTW KennedyD , et al. Validity and reliability of the St. George’s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2013; 144: 623–631.23188518Al-ShairK AthertonGTW KennedyD , et al. Validity and reliability of the St. George’s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2013; 144: 623–631.23188518, Al-ShairK AthertonGTW KennedyD , et al. Validity and reliability of the St. George’s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2013; 144: 623–631.23188518
N. Smith, D. Denning (2010)
Underlying conditions in chronic pulmonary aspergillosis including simple aspergillomaEuropean Respiratory Journal, 37
( JainLR DenningDW . The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52: e133–e137.16427702)
JainLR DenningDW . The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52: e133–e137.16427702JainLR DenningDW . The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52: e133–e137.16427702, JainLR DenningDW . The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52: e133–e137.16427702
( SehgalIS DhooriaS MuthuV , et al. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Expert Rev Respir Med 2020; 14: 715–727.32249630)
SehgalIS DhooriaS MuthuV , et al. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Expert Rev Respir Med 2020; 14: 715–727.32249630SehgalIS DhooriaS MuthuV , et al. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Expert Rev Respir Med 2020; 14: 715–727.32249630, SehgalIS DhooriaS MuthuV , et al. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Expert Rev Respir Med 2020; 14: 715–727.32249630
I. Sehgal, S. Dhooria, V. Muthu, K. Prasad, R. Agarwal (2020)
An overview of the available treatments for chronic cavitary pulmonary aspergillosisExpert Review of Respiratory Medicine, 14
R. Agarwal, Gella Vishwanath, A. Aggarwal, M. Garg, D. Gupta, A. Chakrabarti (2013)
Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literatureMycoses, 56
( DenningDW RiniotisK DobrashianR , et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37: S265–S280.12975754)
DenningDW RiniotisK DobrashianR , et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37: S265–S280.12975754DenningDW RiniotisK DobrashianR , et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37: S265–S280.12975754, DenningDW RiniotisK DobrashianR , et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37: S265–S280.12975754
( SmithNL DenningDW . Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37: 865–872.20595150)
SmithNL DenningDW . Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37: 865–872.20595150SmithNL DenningDW . Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37: 865–872.20595150, SmithNL DenningDW . Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37: 865–872.20595150
P. Jones (2002)
Interpreting thresholds for a clinically significant change in health status in asthma and COPDEuropean Respiratory Journal, 19
( KoyamaK OhshimaN SuzukiJ , et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014; 20: 375–379.24679654)
KoyamaK OhshimaN SuzukiJ , et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014; 20: 375–379.24679654KoyamaK OhshimaN SuzukiJ , et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014; 20: 375–379.24679654, KoyamaK OhshimaN SuzukiJ , et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014; 20: 375–379.24679654
Background and Aims: Patients with chronic pulmonary aspergillosis (CPA) who discontinue antifungal therapy commonly exhibit disease recurrence. We aimed to evaluate the utility of the St. George’s respiratory questionnaire (SGRQ) in predicting the likelihood of clinical recurrence of CPA in patients who come off antifungal therapy. Methods: This audit included CPA patients for whom antifungal therapy was discontinued for at least 1 month. Comparisons were made between the quality of life scores at the time of discontinuation of treatment and at the time of diagnosis of clinical recurrence. The change in patients’ self-assessment scores was also compared. Results: There were 33 cases and 44 controls. Of the 33 cases, 22 (67%) were males with a mean age of 62 ± 13 years. The median for the symptom component of quality of life (QoL) changed from 78.4 at the time of discontinuation of therapy to 83.1 units at the time of diagnosis of clinical failure (p = 0.043), whereas that of the impact and activity components changed from 62.7 to 59.1 units (p = 0.387) and 85.0 to 85.9 units (p = 0.153), respectively. At 12 months, the symptoms domain of SGRQ was able to discriminate between cases of clinical recurrence and controls [area under the curve (AUC) 0.7, 95% confidence interval (CI): 0.6–0.8, p = 0.009]. The proportion of patients in very poor health status increased from 3/11 (9.1%) to 11/33 (33.3%) (p = 0.046). Conclusion: A deteriorating symptoms component of the SGRQ and a worsening of patients’ self-assessment are associated with clinical recurrence. Failure to improve by >8 units in the symptoms domain appear to be a marker of disease recurrence. We propose that the clinical approach to diagnose recurrent CPA would be a combination of clinical history, SGRQ scoring, chest imaging and a workup to exclude other causes of the patients’ symptoms.
Therapeutic Advances in Infectious Disease – SAGE
Published: Jul 28, 2021
Keywords: antifungal; chronic pulmonary aspergillosis; domains; recurrence; St. George’s respiratory questionnaire
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.